Independent medication information Not a pharmacy · Not a substitute for medical advice
Psychedelics / Psychedelic compound

Psilocybin

Identity, uses and research, side effects, dosage context, pricing and online access.

Psychedelic compoundPsychedelics
Reference namePsilocybin
Entry typePsychedelic compound
CategoryPsychedelics
Chemical familyTryptamines
Active metabolitePsilocin
Biological contextCertain mushroom species

DrugRX editorial reference · Sources consulted · Not independently medically reviewed

Psilocybin molecular structure

Psilocybin molecular structure. This diagram does not show a finished medicine or identify a pill.

PubChem / National Library of Medicine · Structure images reusable under PubChem citation guidelines

About Psilocybin

Psilocybin is a psychedelic compound found in certain mushrooms. The chemical, a mushroom species and a named cultivated variety are different things.

Also searched as: Magic mushrooms · Shrooms

PRICE, COST & AVAILABILITY

Buy Psilocybin: pricing & legal access

Psilocybin online: availability & product information

Psilocybin and psilocin are federally listed in Schedule I. Local or state policy changes should not be read as blanket permission for online retail or interstate delivery. No verified retail medicine price is provided here.

Pricing status: No live price feed or verified quote. DrugRX does not sell or dispense products.

Sources: DEA — Controlled substances alphabetical list (October 2026)

DETAILED REFERENCE

Psilocybin information

Psilocybin and mushroom names

Psilocybin-containing mushrooms are often called magic mushrooms. Psilocybe cubensis is one species; Golden Teacher, Penis Envy and B+ are names used for cultivated varieties within it.

Sources: DEA — Psilocybin · P. cubensis genetics and research gaps (2025)

Effects and risks

Changes in perception, nausea, anxiety and panic may occur. Mistaking a poisonous mushroom for a psilocybin-containing one can cause severe poisoning.

Sources: DEA — Psilocybin

Dosage: mushrooms are not standardized medicines

The mass of mushroom material does not reliably state its active-compound content. Laboratory analysis has found variation between and within cultivated strains. DrugRX does not provide a self-use dose.

Sources: Controlled study of 14 P. cubensis strains (2026)

Medical and research context

Clinical investigation of psychedelics involves specific protocols and monitoring. Results for a defined study product cannot establish the benefit of a mushroom variety sold under a commercial name.

Sources: FDA — Psychedelic drugs: clinical investigations

Psilocybin and psilocin

Psilocybin is converted to psilocin in the body. Psilocin’s effects involve serotonin signaling. A measured quantity of purified psilocybin and an equal weight of mushroom material describe entirely different exposures.

Sources: NIH NCCIH — Psilocybin for mental health and addiction

Clinical research versus variety claims

Mental-health research evaluates specified preparations with screening and monitoring. A result for a research product does not demonstrate that Golden Teacher, Penis Envy or another cultivated name has a unique therapeutic effect.

Sources: NIH NCCIH — Psilocybin for mental health and addiction

Species and cultivated names

Psilocybe cubensis names a fungal species. Golden Teacher and B+ are cultivated labels associated with that species. Psilocybin names a compound rather than an organism or a particular mushroom appearance.

LevelExample
CompoundPsilocybin
SpeciesPsilocybe cubensis
Cultivated nameGolden Teacher

Sources: NCBI Taxonomy — Psilocybe cubensis (181762) · P. cubensis genetics and research gaps (2025)

Psilocybin versus psilacetin

4-AcO-DMT, or psilacetin, is a distinct synthetic compound investigated in relation to psilocin metabolism. It should not be relabeled as psilocybin merely because the compounds are pharmacologically related.

Sources: Laboratory study of psilacetin metabolism (2022)

Sources and editorial notes

Prepared by DrugRX using the references linked below. Sources were consulted on 2026-10-31. This page has not been independently reviewed by a clinician. Research findings, medication approval and legal permission are separate questions.

  1. DEA — Psilocybin
  2. P. cubensis genetics and research gaps (2025)
  3. Controlled study of 14 P. cubensis strains (2026)
  4. FDA — Psychedelic drugs: clinical investigations
  5. NIH NCCIH — Psilocybin for mental health and addiction
  6. NCBI Taxonomy — Psilocybe cubensis (181762)
  7. Laboratory study of psilacetin metabolism (2022)
  8. DEA — Controlled substances alphabetical list (October 2026)

Legal information is a dated U.S. reference. Product rules and local laws may change. Where the evidence does not establish a dose, interaction profile or price, the page states that limitation.